Table 1.

Clinical findings in patients with collapsing FSGS after treatment with IFN

Parameter	Patient
	1	2	3	4	5	6	7	8	9	10	11
Age (years)	46	56	41	64	69	36	27	33	37	67	54
Race/ethnicity	Black	Black	Black	Hispanic	Black	Black	Black	Black	Black	Black	Black
Gender	Female	Female	Male	Male	Male	Female	Female	Female	Female	Male	Female
Hypertension	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	Yes	No
Diabetes	No	No	No	No	Yes	No	No	Yes	No	No	No
Medical history	None	Previous IVDA, hypothyroid	Previous IVDA	Previous IVDA	None	Obesity	None	Obesity	None	RA, Raynaud	Obesity, hypothyroid
Indication for IFN	HCV	HCV	HCV	HCV	HCV	Melanoma	MS	MS	MS	IPF	IPF
Duration of IFN therapy (months)	4	2.5	3	2	3	5	Unknown	36	48	18	4
Form of IFN	α	α	α	α	α	α	β-1A	β-1B	β-1A	γ	γ
SCr (mg/dl)	3.2	9.6	1.3	1.5	6.9	1.4	0.7	2.6	2.3	3.5	3.8
24-Hour Uprot (g/d)	10.0	19.4	23.7	4.5	3.3	27.0	16.0	1.9	2.4	4.0	26.5
Serum albumin (g/dl)	0.8	1.4	1.5	1.3	2.3	1.6	0.6	3.3	3.6	3.1	2.0
Edema	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No	Yes
Urine sediment	RBCs	RBCs	RBCs	Bland	Bland	Bland	RBCs	Bland	WBCs	Bland	RBCs
Follow-up duration (months)	6	4	18	53	7	10	NA	54	52	32	2
steroids	Pulse only	Yes	No	No	Pulse only	No		Yes	Yes	No	Yes
additional immunosuppression	No	No	No	No	No	No		No	Cytoxan	No	No
discontinue IFN	Yes	Yes	Yes	Yes	Yes	Yes		Yes	Yes	Yes	Yes
final SCr (mg/dl)	1.2	1.7	HD-dep	1.0	5.6	1.0		1.7	1.2	2.1	1.5
final 24-hour Uprot (g/d)	3.6	10.0		Negative	NA	4.5		0.5	1.4	0.65	NA

HD-dep, hemodialysis dependent; IPF, idiopathic pulmonary fibrosis; IVDA, intravenous drug use; MS, multiple sclerosis; NA, not available; RA, rheumatoid arthritis; RBCs, red blood cells; SCr, serum creatinine; Uprot, urinary protein; WBCs white blood cells.